WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the data presentations on Company and partner experimental therapies to be made at the upcoming American Society of Hematology (ASH) annual meeting to be held December 6-9, 2014 in San Francisco, CA.
Help employers find you! Check out all the jobs and post your resume.
